MD STRATEGIES RESEARCH CENTERS

CURRICULUM VITAE

SIGNATURE:		**DATE:**	
NAME: **TITLE:**	Roy C, Springer, MD Principal Investigator	**DATE UPDATED:**	April 2016

RESEARCH SITE NAME/ ADDRESS:

Main Office: MD Strategies Research Centers 6280 Jackson Drive, Suite 8 San Diego, California 92119	Office: (619) 464-1607 Fax: (619) 303-8456 Email: info@mdsrsandiego.com

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	YEAR(s)	FIELD OF STUDY
American Academy of Family Practice	Fellow	1988	Family Practice
Memorial Baptist Hospital of the University of Texas at Galveston Hospital System. Houston, Texas,	Internship	1968-1969	Family Practice
Universidad Autonoma de Guadalajara, Mexico	MD	1963-1968	Family Practice
College at Texas Western College, AKA, University of Texas at El Paso	College	1959-1963	

BOARD CERTIFIED:

BOARD CERTIFIED/ELIGIBLE	YEAR(s)	SPECIALTY
Board Certified (California)	1969	Family Practice
Board Certified (Mexico)	1972	Family Practice

POSITIONS AND EMPLOYMENT:

2015- Present	Investigator, MD Strategies Research Centers, San Diego, CA
2013-Present	Sub- Investigator, TriWest Research Associates, El Cajon, CA
1998- Present	Physician, Center for Family Health, San Diego, CA
1970- Present	Active Staff, Grossmont Hospital, La Mesa, CA
1981-1983	Chairman Family Practice Dept, Grossmont Hospital, La Mesa, CA
1972-Present	Active Staff, Alvarado Hospital, San Diego, CA
2000- Present	Chairman Family Practice Dept, Alvarado Hospital, San Diego, CA
1979-1980	Chairman Professional Activities Committee, College Park Hospital, San Diego, CA
1999-Present	President, Board of Directors - BEST MSO, San Diego, CA
2005-2008	Secretary, Board of Directors – FHN Health Care, San Diego, CA
1980-1982	Medical Advisor San Diego Chapter of the Leukemia Society of America
1999-2000	Medical Director, International Relief Teams- excursion to Honduras
1994	Medical Director, International Relief Teams- excursion to Rwanda

MEMBERSHIP/ACTIVITIES:

1985- Present	University of California at San Diego – Family Practice Department – Teaching.
1969	Instructor in Shock for incoming interns, Memorial Baptist Hospital Houston, Texas.
1962-1963	Microbiology and Chemistry Lab Instructor, Texas Western.
1958	National Science Fair, Honorable Mention.

CLINICAL RESEARCH EXPERIENCE:

Sub-Investigator

Pfizer Pharmaceuticals: XXXX A Phase 3. Multi-Center, Randomized, Double blind, Controlled study of the long term analgesic efficacy of XXXX alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDS) versus NSAIDS alone in patients with Osteoarthritis of the knee or hip

Ferring Pharmaceuticals:.XXXX A Phase 2, 26 week, Double blind, Randomized, Placebo controlled trial of the efficacy and safety of single XXXX injection 1.2% sodium Hyaluronate for treatment of painful Osteoarthritis of the knee, with optional 26 week open-label extension

King Pharmaceuticals Research and Development, Inc: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of XXXX (XXXX) in Patients with Chronic Low Back Pain

Purdue Pharma: An Open-label, Multicenter Study to Assess the Long -term Safety of XXXX Tablets 20 to 120 mg Once-daily in Subjects with Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain

Purdue Pharma L.P.: A Randomized, Double-blind, Placebo-controlled, Multicenter Trial with an Enriched Study Design to Assess the Efficacy and Safety of XXXX/XXXX Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects with Moderate to Severe Pain due to Chronic Low Back Pain who Require Around-the-clock Opioid Therapy

Abbot Laboratories: A Global Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Study Comparing the Analgesic Efficacy and Safety of XXXX to Placebo in Subjects with Osteoarthritis Pain of the Knee

Covidien: Phase 3 - An Open Label Safety Study of XXXX in Subjects With Osteoarthritis or Chronic Low Back Pain

Eli Lilly: A Phase 3b, multicenter, open-label study to evaluate the long term safety and efficacy of subcutaneous XXXX in patients with Systemic Lupus Erythematous (SLE) (ILLUMINATE-X)

AstraZeneca: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)

Furiex: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of XXXX in the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome

Novo Nordisk Inc.: A Randomized, double-blind, placebo-controlled, multiple dose, phase 2b, 24 week trial followed by an open label extension of XXXX, an anti-IL-20 biologic, in patients with active rheumatoid arthritis who are inadequate responders to Methotrexate

Bayer: A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral XXXX compared to vitamin K antagonist (VKA) for

the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion (Z)

Forest Research Institute, Inc: A Randomized, Double-Blind, Placebo-and-Active-Controlled Study to Evaluate the Safety and Efficacy of XXXX in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Astra Zeneca: Prospective observational study, estimate the rate of inadequate response to laxatives (LIR) in a cohort of patients with OIC

Mannkind Corporation: A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of XXXX Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects with Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12-month Treatment Period with a 2-month Follow-up

Takeda: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral XXXX and 50 mg Compared to Placebo When Used in Combination with Sitagliptin in Subjects with Type 2 Diabetes

Pfizer Inc: Phase 3 Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group evaluation of the efficacy, safety, and tolerability of XXXX, in reducing the occurrence of major cardiovascular events in high risk subjects

Bioventis: A Multicenter, Randomized, Double-Blind, Parallel, Active Controlled Non-Inferiority Clinical Trial Comparing Three Weekly Intra-Articular Injections of XXXX versus Three Weekly Intra-Articular Injections of XXXX for Treatment of Osteoarthritis Pain of the Knee

Kowa Research Institute, Inc.: A Phase III, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Compared With Placebo for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain

Novo Nordisk: A Randomized, double-blind, cross-over trial comparing the safety and efficacy of insulin XXX and insulin XXXX, with or without OADs in subjects with type 2 diabetes

Fidia Farmaceutici S.p.A.: A multic-center, parallel, double-blind, randomized, placebo-controlled study to evaluate the safety and effectiveness of XXXX, a new viscoelastic hydrogel, for the treatment of osteoarthritis of the knee

Teva Branded Pharmaceutical Products R&D, Inc.: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied XXXX (4% and 8% w/w Ointment) in Patients with Primary Ostearthritis Affecting a Single Knee

Amgen: A Prospective, Observational study for the Psychometric Evaluation of XXXX Migraine-Related Functional Impact Instrument in Subjects with Episodic and Chronic Migraine

Merck: A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of XXXX/XXXX MDI Fixed Dose Combination versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults with Persistent Asthma

Astra Zeneca: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, Phase 3 Trila to Evaluate the Safety and Efficacy of Once Weekly XXXX Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients with Type 2 Diabetes Who have Inadequate Glycemic Control on Basal Insulin Glargine with or without Metformin

Vertex Pharmaceuticals Incorporated: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of 2 dose levels of XXXX administered as Monotherapy and One Dose Level of XXXX Administered in combination with Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Rhythm: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of XXXX Administered to Patients with vomitting Symptoms and Moderate to Severe Diabetic Gastroparesis

Sanofi Pharmaceuticals: Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog XXXX to Humalog® in Adult Patients with Type 2 Diabetes Mellitus also Using Insulin Glargine

Centrexion: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXX in Subjects with Painful Intermetatarsal Neuroma (Morton's Neuroma)

Genzyme: Randomized open label study assessing the effect of a novel smartphone application and a wearable activity monitor on mobility compared with standard follow up and a wearable activity monitor in patients with osteoarthritis (OA) of the knee treated with Synvisc-One®

AbbVie Inc.: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study comparing the safety and efficacy of XXXX to placebo in subjects with Erosive Hand Osteoarthritis

AstraZeneca AB: A 52-Week, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of XXXX in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β^2-Agonist

Regeneron: A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX in Patients with Pain due to Osteoarthritis of the Knee or Hip

AbbVie: A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of XXXX in Patients with Knee Osteoarthritis

King: A Multi-Center, Primary Care-Based, Open-Label, Study to Assess the Success of Converting Opiod Experienced patients, with Chronic, Moderate to Severe Pain, to EMBEDA™ Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse, and Diversion (ConvERT)

Titan: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence

Principal-Investigator

Paratek: A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral XXXX to Oral XXXX for Treating Adult Subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Shionogi: A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of XXXX Compared with Placebo or XXXX mg Twice Daily for 5 Days in Otherwise Healthy Patients with Influenza

Shionogi: A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of XXXX Compared with Placebo or XXXX 75 mg Twice Daily for 5 Days in Patients with Influenza at High Risk of Influenza Complications

Kowa: XXXX to Reduce Cardiovascular Outcomes by reducing triglycerides in patients with diabetes.

M14-702 - A Phase 3 Study to Evaluate the Safety and Efficacy of XXXX in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain

M16-283: A Phase 3b Study to Evaluate the Long-Term Efficacy and Safety of XXXX in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women

Observational Study of Patients with Hypothyroidism Switching from Levothyroxine to XXXX